Marked improvement in nail psoriasis during treatment with adalimumab

Irla, N; Yawalkar, N (2009). Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology, 219(4), pp. 353-6. Basel: Karger 10.1159/000252853

Full text not available from this repository. (Request a copy)

BACKGROUND: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients' quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor alpha with high affinity and specificity. OBSERVATIONS: We report two cases of rapid improvement in nail psoriasis under adalimumab monotherapy with maintained effectiveness despite intermittent treatment as well as long remission after therapy discontinuation. CONCLUSION: The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Yawalkar, Nikhil

ISSN:

1018-8665

ISBN:

19851059

Publisher:

Karger

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:09

Last Modified:

04 May 2014 23:22

Publisher DOI:

10.1159/000252853

PubMed ID:

19851059

Web of Science ID:

000272328700013

URI:

https://boris.unibe.ch/id/eprint/30395 (FactScience: 193768)

Actions (login required)

Edit item Edit item
Provide Feedback